Anergis to Present Dose-Dependent Immunological Effects of Ultra-Fast Allergy Immunotherapy AllerT at the AAAAI annual meeting
- Marked increases in Bet v 1 specific IgG4 were dose-dependent in 213 patients allergic to birch pollen
EPALINGES, Switzerland, March 1, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it will present new dose-ranging data on its lead-product AllerT at the AAAAI annual meeting. The annual meeting of the AAAAI (American Academy of Allergy, Asthma and Immunology) will take place in Atlanta, USA, from March 3 to 6, 2017.
The following scientific communication will be presented during the meeting:
Presentation Title: "Dose dependent increase of Bet v 1 specific IgG4 after Bet v 1 COP therapy"
Presenter: Alexander Kettner, Ph.D
Time and Date: Monday, March 6, 2017, 9.45 am-10.45 am
Session: 4210 ; Allergen Extracts and Other Forms of Immunotherapy
Poster #: 804
Location: Georgia World Congress Center, Level One, South Exhibit Hall B2
Abstract is available on the AAAAI meeting website: http://annualmeeting.aaaai.org